Showing results for: Post-Surgery Articles & Analysis

You wish the best for your patients, and following surgery or treatment, it is imperative to understand how their bodies are reacting. Obviously this concerns following up at intervals. However, patients are often under the impression that following up is unnecessary and expensive if they feel fine. The cardiac monitor experts at Medicomp take a look at the realities of patient follow-ups. ...

By Medicomp Inc.

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...

By ITM Isotope Technologies Munich SE

The new Director of Breast Surgery and Women’s Health for the breast surgery center at the Albert Einstein Healthcare Network has a very simple reason for dedicating his life to his profession. “I became a surgeon because when I see a problem, I want to fix it, and with surgery we’re often the last line of defense when dealing with breast cancer,” Dr. Archit Naik admitted. ...

By Dilon Technologies Inc.

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office on its lead product ENA-001 and related compounds for the reversal of respiratory depression from non-opioid ...

By Enalare Therapeutics Inc.

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has dosed the first subject with its lead product ENA-001 in a propofol-induced respiratory depression study. This study aims to demonstrate the ability of ENA-001 to reverse respiratory depression induced ...

By Enalare Therapeutics Inc.

An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgicalAuthors (in order): Halla Nimeiri1, Amanda Young1, Russell Madison1, Alexander Fine1, Ole Gjoerup1, Fotios Loupakis2, Matteo Fassan2,3, Sara Lonardi2, Shruti Sharma4, Hsin-Ta Wu4, Alexey Aleshin4, Elise Renkonen1, Priti Hegde11Foundation Medicine Inc, 2Istituto Oncologico Veneto ...

By Foundation Medicine, Inc.

TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...

By TISSIUM

Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company focused on better treatment of Hydrocephalus and cerebrospinal fluid dysfunctions. The separation and ...

By Anuncia Medical, Inc.

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant will be used to further the development of ENA001, Enalare's ...

By Enalare Therapeutics Inc.

SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. Key learnings from the market ...

By Mediprint Ophthalmics

Dr. Elizabeth Revesz has a unique background as an artist and sculptor. She was able to translate her precision, and her ability to see things in three dimensions, into a highly successful career in medicine. But once in the medical field, Dr. Revesz went further to find her true calling. “Medicine is great, but surgery is actually where I feel the most comfortable,” the physician ...

By Dilon Technologies Inc.

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the treatment of Apnea of Prematurity. Enalare is planning to develop this unique agnostic ...

By Enalare Therapeutics Inc.

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. The objective of the study was to demonstrate the ability of ENA001 ...

By Enalare Therapeutics Inc.

As a patient facing breast cancer surgery, you should know that precise "marking" of your cancer surgical site is an important part of your treatment. A marker is a device inserted at the surgical site. Precision in marking helps make sure you retain as much normal breast tissue as possible with the surgery. This ultimately leads to best overall post-surgical care by your wellness team. A new ...

By Videra Surgical Inc.

Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of intractable chronic pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, launches its ‘Engineered to be More’ branding campaign. The campaign highlights the award-winning engineering ...

By Nalu Medical, Inc.

- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief ...

By Palisade Bio

BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced that it has entered into a Development, Supply, Distribution Agreement with Avanos Medical, Inc. (NYSE: AVNS, “Avanos”). Under the agreement, the parties will work together to obtain appropriate regulatory approvals and commercialize self-contained, infusible, non-opioid post-operative pain pharmaceutical ...

By BioQ Pharma

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next ...

By Palisade Bio

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative ...

By Merck & Co., Inc.,

Head and neck cancer surgery presents a number of unique challenges, not only for the surgeon but for the radiation oncologist who will subsequently treat those patients. Great care with an emphasis on precision must be taken to ensure that critical structures and tissues avoid collateral damage when possible. However, given the surgical site often lies in soft tissue, exact identification of the ...

By Videra Surgical Inc.